Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).

Children taking once-weekly NGENLA for 1 year had on average a similar growth rate to children taking once-daily growth hormone treatment.

Not an actual patient.

NGENLA has the broadest preferred commercial coverage in the US of any once-weekly pediatric growth hormone treatment.

Learn more

For children with pediatric growth hormone deficiency (pGHD), NGENLA offers:

Once-a-week injections, taken on the same day each week

~85% fewer doses, compared to daily growth hormone

Dosing any time of the day, not just at night   

Similar height
results and side effects to daily growth hormone treatment

See NGENLA results 

Was your child recently
diagnosed?

>

Considering treatment or
switching to NGENLA?

>

Is your child prescribed
NGENLA?

>

  • Your child’s growth

  • NGENLA prefilled pen

  • money-sign-icon

    Financial support

  • resource-document-icon

    Helpful resources

Not actual patients.

Your child’s growth

Children grow at different rates, but most reach height milestones by certain times. Understanding how your child measures up can help you make informed decisions with your doctor about your child's care.

Find out more Loading

NGENLA prefilled pens are easy to use 

The once-weekly NGENLA prefilled pen comes in 2 dosage strengths. Your doctor will decide which strength is right for your child.

  • Prefilled pens with the strength that is right for your child
  • Low injection volume (<1 mL)
  • Fine needle gauge
  • No reconstitution required
Find out more Loading

NGENLA Copay Program

Eligible commercially insured patients may pay $0 per prescription.*

Check copay eligibility Loading

*Eligibility required. Annual savings up to $6,000. State and federal beneficiaries not eligible. Click here for terms and conditions.

Helpful resources

Download these printable resources:

  • Patient Brochure to better understand this treatment
  • FAQs to answer your questions
  • How to Use NGENLA Placemat with step-by-step instructions to guide you through the injection process
Check out NGENLA resources Loading

Important Safety Information & Use

COLLapSE

IMPORTANT SAFETY

INFORMATION & USE
INDICATION
NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).   
IMPORTANT SAFETY INFORMATION
  • Growth hormone should not be used in children after the growth plates have closed.
  • Growth hormone should not be used in children with some types of eye problems
    caused by diabetes (diabetic retinopathy).
  • Growth hormone should not be used in children who have cancer or other tumors.
  • Growth hormone should not be used in children who are critically ill because of some
    types of heart or stomach surgery, trauma, or breathing (respiratory) problems.
  • Growth hormone should not be used in children with Prader-Willi syndrome who are
    very overweight or have breathing problems including sleep apnea.
  • NGENLA should not be used by children who have had an allergic reaction to
    somatrogon-ghla or any of the ingredients in NGENLA. Look for prompt medical
    attention in case of an allergic reaction.
  • Some children have developed diabetes mellitus while taking growth hormone. Dosages
    of diabetes medicines may need to be adjusted during treatment with NGENLA.
    Children should be watched carefully if NGENLA is given along with glucocorticoid
    therapy and/or other drugs that are processed by the body in the same way.
  • In childhood cancer survivors, treatment with growth hormone may raise the likelihood
    of a new tumor, particularly some benign (non-cancerous) brain tumors. This likelihood
    may be higher in children who were treated with radiation to the brain or head. Your
    child’s health care provider will need to check your child for a return of cancer or a
    tumor.
  • Children treated with growth hormone have had increased pressure in the brain. If your
    child has headaches, eye problems, nausea (feeling like you are going to be sick), or
    vomiting, contact your child’s health care provider.
  • NGENLA may decrease thyroid hormone levels. Decreased thyroid hormone levels may
    change how well NGENLA works. Your child’s health care provider will do blood tests to
    check your child’s hormone levels.
  • Children treated with growth hormone should be checked regularly for low serum
    cortisol levels and/or the need to increase the dose of the glucocorticoids they are
    taking.
  • In children experiencing fast growth, curvature of the spine may develop or worsen. This
    is also called scoliosis. Children with scoliosis should be checked regularly to make sure
    their scoliosis does not get worse during their growth hormone therapy.
  • Use a different area on the body for each injection. This can help to avoid skin problems
    such as lumpiness or soreness.
  • Growth hormone treatment may cause serious and constant stomach (abdominal) pain.
    This could be a sign of pancreatitis. Tell your child’s health care provider if your child has
    any new stomach (abdominal) pain.
  • In studies of NGENLA in children with GHD, side effects included injection site reactions
    such as pain, swelling, rash, itching, or bleeding. Other side effects were the common
    cold, headache, fever (high temperature), low red blood cells (anemia), cough, vomiting,
    decreased thyroid hormone levels, stomach pain, rash, or throat pain.
  • A health care provider will help you with the first injection. He or she will also train you
    on how to inject NGENLA.
  • Rx only

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2025 Pfizer Inc. All rights reserved.
PP-SMT-USA-0429